Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension

Nephrology Dialysis Transplantation

Volumn 14, Issue SUPPL. 4, 1999, Pages 25-27

  Plum, J ^a   Bunten B ^a   Nemeth R ^a   Grabensee, B ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; VALSARTAN;

ADULT; AGED; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; MEAN ARTERIAL PRESSURE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

EID: 0032772887     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.suppl_4.25     Document Type: Conference Paper

References (6)

1. Timmermans PBMWM, Wong PC, Chiu AT et al. Angiotensin II and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251
2. Bauer JH, Reams GP. The angiotensin II type 1 receptor antogonists. Arch Intern Med 1995; 155: 1361-1368
3. Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming systems in humans. Am J Hypertension 1996; 9: 277-84
4. Burnier M, Waeber B, Brunner R. The advantages of angiotensin II antagonism. J Hypertension 1994; 12 [Suppl 2]: 37-42
5. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan in patients over 65 with heart failure (Evaluation of Losartan in the Elderly, ELITE). Lancet 1997; 349: 747-752
6. Deen WM, Bridges CR, Bremner BM, Myers BD. Heterogenous model of glomerular size selectivity: application to normal and nephrotic humans. Am J Physiol 1985; 249: 347-389